|
Dr. Royston is a Managing Member at Forward Ventures, an investor in Favrille. As an entrepreneur and investor, Dr. Royston has played a leading role in the development of the biotechnology industry. In 1978 he founded Hybritech, which was subsequently purchased by Eli Lilly. He was one of the founders of IDEC, which is now one of the top ten biotechnology companies in the U.S. He has been recently involved as a founding director of a number of major successes such as GeneSys Therapeutics (now CellGenesys [NASDAQ:CEGE]), GenQuest (acquired by Corixa [NASDAQ:CRXA]); Combichem ([NASDAQ:CCHM] acquired by DuPont); Sequana Therapeutics (now Axys Pharmaceuticals [NASDAQ:AXPH] and Corixa [NASDAQ:CRXA]. In 1994 he received the Ernst & Young San Diego Entrepreneur of the Year award. Dr. Royston is a nationally recognized physician-scientist in cancer immunology with over 100 publications. He received B.S. and M.D degrees from Johns Hopkins University and completed his training in internal medicine and medical oncology at Stanford University. His academic research career has included positions at the NIH and University of California, San Diego. From 1990-2000 he was President and CEO of the Sidney Kimmel Cancer Center, which he founded. In 1997, he was appointed by President Clinton to the National Cancer Advisory Board. | 